|
1
|
Klein CA and Stoecklein NH: Lessons from
an aggressive cancer: evolutionary dynamics in esophageal
carcinoma. Cancer Res. 69:5285–5288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mao WM, Zheng WH and Ling ZQ:
Epidemiologic risk factors for esophageal cancer development. Asian
Pac J Cancer Prev. 12:2461–2466. 2011.PubMed/NCBI
|
|
3
|
Lepage C, Rachet B, Jooste V, Faivre J and
Coleman MP: Continuing rapid increase in esophageal adenocarcinoma
in England and Wales. Am J Gastroenterol. 103:2694–2699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tew WP, Kelsen DP and Ilson DH: Targeted
therapies for esophageal cancer. Oncologist. 10:590–601. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yeung K, Seitz T, Li S, Janosch P,
McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H,
Sedivy JM and Kolch W: Suppression of Raf-1 kinase activity and MAP
kinase signalling by RKIP. Nature. 401:173–177. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yeung KC, Rose DW, Dhillon AS, Yaros D,
Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W and Sedivy
JM: Raf kinase inhibitor protein interacts with NF-kappaB-inducing
kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol.
21:7207–7217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deiss K, Kisker C, Lohse MJ and Lorenz K:
Raf kinase inhibitor protein (RKIP) dimer formation controls its
target switch from Raf1 to G protein-coupled receptor kinase (GRK)
2. J Biol Chem. 287:23407–23417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
al-Mulla F, Bitar MS, Taqi Z, Rath O and
Kolch W: RAF kinase inhibitory protein (RKIP) modulates cell cycle
kinetics and motility. Mol Biosyst. 7:928–941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma J, Li F, Liu L, Cui D, Wu X, Jiang X
and Jiang H: Raf kinase inhibitor protein inhibits cell
proliferation but promotes cell migration in rat hepatic stellate
cells. Liver Int. 29:567–574. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keller ET: Role of Raf kinase inhibitor
protein in pathophysiology of prostate cancer. For Immunopathol Dis
Therap. 2:89–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khamis ZI, Iczkowski KA and Sang QX:
Metastasis suppressors in human benign prostate, intraepithelial
neoplasia, and invasive cancer: their prospects as therapeutic
agents. Med Res Rev. 32:1026–1077. 2012. View Article : Google Scholar
|
|
12
|
Bevilacqua E, Frankenberger CA and Rosner
MR: RKIP suppresses breast cancer metastasis to the bone by
regulating stroma-associated genes. Int J Breast Cancer.
2012:1247042012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Granovsky AE and Rosner MR: Raf kinase
inhibitory protein: a signal transduction modulator and metastasis
suppressor. Cell Res. 18:452–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Klysik J, Theroux SJ, Sedivy JM, Moffit JS
and Boekelheide K: Signaling crossroads: the function of Raf kinase
inhibitory protein in cancer, the central nervous system and
reproduction. Cell Signal. 20:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zeng L, Imamoto A and Rosner MR: Raf
kinase inhibitory protein (RKIP): a physiological regulator and
future therapeutic target. Expert Opin Ther Targets. 12:1275–1287.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Yang YH, Wang AQ, Yao B, Xie G,
Feng G, Zhang Y, Cheng ZS, Hui L, Dai TZ, Du XB and Wang D:
Immunohistochemical detection of the Raf kinase inhibitor protein
in nonneoplastic gastric tissue and gastric cancer tissue. Med
Oncol. 27:219–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chatterjee D, Sabo E, Tavares R and
Resnick MB: Inverse association between Raf kinase inhibitory
protein and signal transducers and activators of transcription 3
expression in gastric adenocarcinoma patients: implications for
clinical outcome. Clin Cancer Res. 14:2994–3001. 2008. View Article : Google Scholar
|
|
18
|
Zlobec I, Baker K, Minoo P, Jass JR,
Terracciano L and Lugli A: Node-negative colorectal cancer at high
risk of distant metastasis identified by combined analysis of lymph
node status, vascular invasion, and Raf-1 kinase inhibitor protein
expression. Clin Cancer Res. 14:143–148. 2008. View Article : Google Scholar
|
|
19
|
Minoo P, Zlobec I, Baker K, Tornillo L,
Terracciano L, Jass JR and Lugli A: Loss of raf-1 kinase inhibitor
protein expression is associated with tumor progression and
metastasis in colorectal cancer. Am J Clin Pathol. 127:820–827.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Al-Mulla F, Hagan S, Behbehani AI, Bitar
MS, George SS, Going JJ, García JJ, Scott L, Fyfe N, Murray GI and
Kolch W: Raf kinase inhibitor protein expression in a survival
analysis of colorectal cancer patients. J Clin Oncol. 24:5672–5679.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zlobec I, Baker K, Terracciano L, Peter S,
Degen L, Beglinger C and Lugli A: Two-marker protein profile
predicts poor prognosis in patients with early rectal cancer. Br J
Cancer. 99:1712–1717. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim HS, Won KY, Kim GY, Kim SC, Park YK
and Kim YW: Reduced expression of Raf-1 kinase inhibitory protein
predicts regional lymph node metastasis and shorter survival in
esophageal squamous cell carcinoma. Pathol Res Pract. 208:292–299.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Birner P, Jesch B, Schultheis A and
Schoppmann SF: RAF-kinase inhibitor protein (RKIP) downregulation
in esophageal cancer and its metastases. Clin Exp Metastasis.
29:551–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao C, Pang L, Ren C and Ma T: Prognostic
value of raf kinase inhibitor protein in esophageal squamous cell
carcinoma. Pathol Oncol Res. 18:471–477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): a population-based study. Lancet
Oncol. 13:790–801. 2012.PubMed/NCBI
|
|
26
|
Lambert R, Saito H, Lucas E and
Sankaranarayanan R: Survival from digestive cancer in emerging
countries in Asia and Africa. Eur J Gastroenterol Hepatol.
24:605–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bosetti C, Levi F, Ferlay J, Garavello W,
Lucchini F, Bertuccio P, Negri E and La Vecchia C: Trends in
oesophageal cancer incidence and mortality in Europe. Int J Cancer.
122:1118–1129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brown LM, Devesa SS and Chow WH: Incidence
of adenocarcinoma of the esophagus among white Americans by sex,
stage, and age. J Natl Cancer Inst. 100:1184–1187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shibata A, Matsuda T, Ajiki W and Sobue T:
Trend in incidence of adenocarcinoma of the esophagus in Japan,
1993–2001. Jpn J Clin Oncol. 38:464–468. 2008.PubMed/NCBI
|
|
30
|
Woods Ignatoski KM, Grewal NK, Markwart
SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME and Keller ET:
Loss of Raf kinase inhibitory protein induces radioresistance in
prostate cancer. Int J Radiat Oncol Biol Phys. 72:153–160.
2008.PubMed/NCBI
|
|
31
|
Yun J, Frankenberger CA, Kuo WL, Boelens
MC, Eves EM, Cheng N, Liang H, Li WH, Ishwaran H, Minn AJ and
Rosner MR: Signalling pathway for RKIP and Let-7 regulates and
predicts metastatic breast cancer. EMBO J. 30:4500–4514. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zaravinos A, Bizakis J and Spandidos DA:
RKIP and BRAF aberrations in human nasal polyps and the adjacent
turbinate mucosae. Cancer Lett. 264:288–298. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC,
Yang J and Yao Z: Effects of raf kinase inhibitor protein
expression on metastasis and progression of human breast cancer.
Mol Cancer Res. 7:832–840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li HZ, Wang Y, Gao Y, Shao J, Zhao XL,
Deng WM, Liu YX, Yang J and Yao Z: Effects of raf kinase inhibitor
protein expression on metastasis and progression of human
epithelial ovarian cancer. Mol Cancer Res. 6:917–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dangi-Garimella S, Yun J, Eves EM, Newman
M, Erkeland SJ, Hammond SM, Minn AJ and Rosner MR: Raf kinase
inhibitory protein suppresses a metastasis signalling cascade
involving LIN28 and let-7. EMBO J. 28:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Akutsu Y and Matsubara H: The significance
of lymph node status as a prognostic factor for esophageal cancer.
Surg Today. 41:1190–1195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sgourakis G, Gockel I, Lyros O, Lanitis S,
Dedemadi G, Polotzek U, Karaliotas C and Lang H: The use of neural
networks in identifying risk factors for lymph node metastasis and
recommending management of t1b esophageal cancer. Am Surg.
78:195–206. 2012.PubMed/NCBI
|
|
38
|
Ben-Neriah Y and Karin M: Inflammation
meets cancer, with NF-κB as the matchmaker. Nat Immunol.
12:715–723. 2011.
|
|
39
|
Bromberg J and Wang TC: Inflammation and
cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Beshir AB, Ren G, Magpusao AN, Barone LM,
Yeung KC and Fenteany G: Raf kinase inhibitor protein suppresses
nuclear factor-κB-dependent cancer cell invasion through negative
regulation of matrix metalloproteinase expression. Cancer Lett.
299:137–149. 2010.
|
